한글목차

세계의 HIV 진단 시장은 2022년에 19억 달러로 평가되었고, 2023년부터 2032년까지 연평균 복합 성장률(CAGR) 3.9%로 성장할 전망이며, 2032년에는 27억 달러에 이를 것으로 예측됩니다.

후천성 면역 결핍 증후군(AIDS)을 일으키는 바이러스인 인간 면역 결핍 바이러스(HIV)에 감염되어 있는지 여부를 판정하는 순서입니다. HIV 검사는 혈액량, 타액, 소변에 HIV 항체, 항원, 유전자(RNA 또는 DNA)가 있는지 여부를 확인하기 위해 여러 가지 방법 및 방법론을 사용합니다. 기본적으로 HIV 검사의 초점은 감염된 사람을 매우 조기에 발견하고 적절한 의료 조치를 제공하고 다른 사람이 감염되는 것을 방지하는 것입니다.

HIV 진단의 동향은 지역 상황, 인구 역학, 예방 조치, 의료 접근 등의 요인에 의해 형성된 다양한 상황을 보여줍니다. 특히, 예방 및 치료 프로그램이 충실하고 있는 몇몇 고소득 국가에서는 인지도의 향상, 검사의 보급, 치료 액세스의 개선, 노출 전 예방약(Pre-Exposure Prophylaxis : PrEP) 등의 예방 전략에 의해 새로운 HIV 진단이 감소하고 있습니다. 예를 들어 아시아태평양경제협력개발기구(OECD)에 따르면 2022년 HIV 감염 유병률은 방글라데시, 몽골, 뉴질랜드, 스리랑카에서는 15-49세 성인의 0.1% 미만, 2020년 태국에서는 15-49세 성인의 1%와 중요한 변동이 있습니다. HIV 유병률은 낮지만 아시아태평양 인구가 많기 때문에 2021년 보고 국가 및 지역 HIV와 함께 사는 사람의 절대수는 220만명 이상으로 많았습니다.

HIV의 예방과 치료에는 진보가 보이지만, 다른 남성과 성교섭을 가진 남성(MSM), 트랜스젠더, 인종적 마이너리티 등 일부 특정 집단이 여전히 높은 HIV 진단률을 보고하고 있다는 점에 유의하는 것이 중요합니다. 이러한 격차는 케어의 불평등을 부조하고 있습니다. 동시에, 약물 주사 및 건강 관리 서비스에 접근하기 어려운 요인으로 인해 특정 집단과 지역에서 새로운 HIV 유행이 발생하고 있습니다. 또, 사하라 이남의 아프리카 등 특정 지역에서는 충분한 성교육을 받지 못하고 의료에 대한 액세스도 제한되어 있기 때문에 젊은이는 여전히 취약합니다.

HIV 진단 시장은 모드, 검사 유형, 최종 용도, 지역으로 구분됩니다. 모드별로 시장은 자체 검사형과 실험실형으로 구분됩니다. 검사 유형별로 시장은 항체 및 항원 검사, 바이러스 부하 검사 및 핵산 검사, CD4 검사, 유아 조기 진단용 검사로 분별됩니다. 항체 및 항원 검사는 또한 HIV-1 스크리닝 검사, HIV-1 항체 확인 검사, HIV-2 & Group Of 진단 검사로 분별됩니다. 최종 용도별로 시장은 진단 실험실, 병원 및 클리닉, 가정 환경으로 분류됩니다. 지역별로 HIV 진단 시장은 북미, 유럽, 아시아태평양, 라틴아메리카, 중동, 아프리카로 구분됩니다.

이해관계자를 위한 주요 이점

• 본 보고서에서는 2022년부터 2032년까지 HIV 진단 시장 분석 시장 부문, 현재의 동향, 추정 및 동향 분석, 역학을 정량적으로 분석하여 HIV 진단 시장의 유력한 시장 기회를 확인합니다.
• 시장 성장 촉진요인, 시장 성장 억제요인, 시장 기회와 관련된 정보와 함께 시장 조사를 제공합니다.
• Porter's Five Forces 분석은 이해관계자가 이익에 중점을 둔 비즈니스 결정을 내리고 공급업체와 구매자의 네트워크를 강화할 수 있도록 구매자 및 공급업체의 잠재력을 강조합니다.
• HIV 진단 시장의 세분화를 자세히 분석하면 시장 기회를 파악할 수 있습니다.
• 각 지역의 주요 국가는 세계 시장에 대한 수익 공헌도에 따라 매핑됩니다.
• 시장 기업 포지셔닝은 벤치마크를 용이하게 하고 시장 기업의 현재 위치를 명확하게 이해할 수 있습니다.
• 이 보고서에는 지역별 및 세계의 HIV 진단 시장 동향, 주요 기업, 시장 부문, 응용 분야 및 시장 성장 전략 분석이 포함되어 있습니다.

보고서 맞춤설정 가능성(별도 비용 및 일정 필요)

• 고객의 관심에 따른 기업 프로파일 추가
• 국가별 또는 지역별 추가 분석-시장 규모 및 예측
• 평균 판매 가격 분석 및 프라이스 포인트 분석
• 크리스 크로스 부문 분석-시장 규모 및 예측
• 기업 프로파일의 확장 목록
• 과거 시장 데이터
• 주요 기업의 상세(소재지, 연락처, 공급자 및 벤더 네트워크 등을 포함한 엑셀 형식)
• 세계, 지역 및 국가 수준에서 기업의 시장 점유율 분석
• SWOT 분석

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장 정의 및 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 성장 촉진요인
  • 억제요인
  • 기회

제4장 HIV 진단 시장 : 모드별

• 개요
• 자기 검사
• 랩베이스

제5장 HIV 진단 시장 : 검사 유형별

• 개요
• 항체 및 항원검사
  • 항체 및 항원 검사 유형별 HIV 진단 시장
• 바이러스량 검사 및 핵산 검사
• CD4 검사
• 유아 조기 진단용 검사

제6장 HIV 진단 시장 : 최종 용도별

• 개요
• 진단 실험실
• 병원 및 진료소
• 재택 환경

제7장 HIV 진단 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 일본
  • 중국
  • 호주
  • 인도
  • 한국
  • 기타
• 라틴아메리카, 중동 및 아프리카
  • 브라질
  • 사우디아라비아
  • 남아프리카
  • 기타

제8장 경쟁 구도

• 서문
• 주요 성공 전략
• 주요 10개사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2022년)

제9장 기업 프로파일

• Abbott Laboratories
• Gilead Sciences, Inc.
• Merck & Co. Inc.
• Danaher Corporation
• Mylan NV
• F Hoffman La Roche Ltd
• Siemens Healthcare Private Limited
• Qiagen NV.
• Bio-Rad Laboratories, Inc.
• Hologic Inc.

영문목차

The global HIV diagnosis market was valued at $1.9 billion in 2022, and is projected to reach $2.7 billion by 2032, growing at a CAGR of 3.9% from 2023 to 2032.

It is a procedure that determines if a person has contracted the Human Immunodeficiency Virus (HIV), a virus that leads to acquired immunodeficiency syndrome (AIDS). Several approaches and methodologies are used in HIV testing to establish whether an individual has HIV antibodies, antigens, or gene (RNA or DNA) in his blood volumes, saliva, and urine. Essentially, the focus of HIV testing is aimed at detecting infected persons very early, offering them relevant medical attention as well as preventing others from acquiring the infection.

Trends in HIV diagnosis exhibit a diverse landscape shaped by factors including geographical location, demographics, prevention measures, and healthcare accessibility. Notably, several high-income countries with robust prevention and treatment programs have witnessed a decline in new HIV diagnoses due to heightened awareness, widespread testing, improved treatment access, and preventive strategies such as Pre-exposure prophylaxis (PrEP). For instance, in 2022, according to Organization for Economic Cooperation and Development (OECD) in Asia-Pacific, the prevalence of HIV infection varied importantly, ranging from less than 0.1% of adults aged 15 to 49 in Bangladesh, Mongolia, New Zealand, and Sri Lanka to 1% of adults aged 15 to 49 in Thailand in 2020. Although HIV prevalence was low, the absolute number of people living with HIV was high at more than 2.2 million in reporting countries and territories in 2021, owing to Asia-Pacific's large population.

Although there have been advancements in the prevention and treatment of HIV, it is important to note that some specific populations such as men who have sexual intercourse with other men (MSM), transgender people, and racial minorities continue to report high rates of HIV diagnoses. These disparities underscore prevailing inequalities in care. At the same time, new HIV epidemics are emerging within certain populations or regions, owing to factors such as injecting drugs and difficulties in accessing healthcare services. Young people also remain vulnerable in certain areas such as sub-Saharan Africa as they lack adequate sex education and limited access to health care.

The HIV diagnosis market is segmented into mode, test type, end use, and region. By mode, the market is segregated into self-test and lab based. By test type the market is segregated into antibody/antigen test, viral load test/nucleic acid test, CD4 test, and test for early infant diagnosis. Antibody/antigen test is further segregated into HIV-1 screening tests, HIV-1 antibody confirmatory tests, and HIV-2 & Group Of diagnostic tests. By end use, the market is segregated into diagnostic laboratories, hospitals & clinics, and home settings. By region, the HIV diagnosis market is segmented into North America, Europe, Asia-Pacific, and LAMEA.

Major companies operating in this market include Abbott, Gilead Sciences, Inc., Merck & Co. Inc., Beckman Coulter, Inc., Mylan N.V., F. Hoffman-La Roche Ltd., Siemens Healthcare GmbH, QIAGEN, Bio-Rad Laboratories, Inc., and Hologic. Key players have adopted product launch and collaboration as their key strategy to improve the product portfolio of the testosterone replacement therapy market.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hiv diagnosis market analysis from 2022 to 2032 to identify the prevailing hiv diagnosis market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the hiv diagnosis market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global hiv diagnosis market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Average Selling Price Analysis / Price Point Analysis
• Criss-cross segment analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)
• Market share analysis of players at global/region/country level
• SWOT Analysis

Key Market Segments

By Mode

• Self-test
• Lab-based

By Test Type

• Antibody/Antigen Test
  • Type
  • HIV-1 Screening Tests
  • HIV-1 Antibody Confirmatory Tests
  • HIV-2 and Group O Diagnostic Tests
• Viral load test/Nucleic Acid Test
• CD4 test
• Test for Early Infant Diagnosis

By End-use

• Diagnostic Laboratories
• Hospitals and Clinics
• Home Settings

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Abbott Laboratories
• Gilead Sciences, Inc.
• Merck & Co. Inc.
• Danaher Corporation
• Mylan N.V.
• F Hoffman La Roche Ltd
• Siemens Healthcare Private Limited
• Qiagen NV.
• Bio-Rad Laboratories, Inc.
• Hologic Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
• 3.4. Market dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: HIV DIAGNOSIS MARKET, BY MODE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Self-test
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Lab-based
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country

CHAPTER 5: HIV DIAGNOSIS MARKET, BY TEST TYPE

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Antibody/Antigen Test
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
  • 5.2.4. Antibody/Antigen Test HIV Diagnosis Market by Type
• 5.3. Viral load test/Nucleic Acid Test
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. CD4 test
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Test for Early Infant Diagnosis
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country

CHAPTER 6: HIV DIAGNOSIS MARKET, BY END-USE

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Diagnostic Laboratories
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Hospitals and Clinics
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Home Settings
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: HIV DIAGNOSIS MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Mode
  • 7.2.3. Market size and forecast, by Test Type
  • 7.2.4. Market size and forecast, by End-use
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Mode
    • 7.2.5.1.2. Market size and forecast, by Test Type
    • 7.2.5.1.3. Market size and forecast, by End-use
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Mode
    • 7.2.5.2.2. Market size and forecast, by Test Type
    • 7.2.5.2.3. Market size and forecast, by End-use
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Mode
    • 7.2.5.3.2. Market size and forecast, by Test Type
    • 7.2.5.3.3. Market size and forecast, by End-use
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Mode
  • 7.3.3. Market size and forecast, by Test Type
  • 7.3.4. Market size and forecast, by End-use
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Mode
    • 7.3.5.1.2. Market size and forecast, by Test Type
    • 7.3.5.1.3. Market size and forecast, by End-use
    • 7.3.5.2. France
    • 7.3.5.2.1. Market size and forecast, by Mode
    • 7.3.5.2.2. Market size and forecast, by Test Type
    • 7.3.5.2.3. Market size and forecast, by End-use
    • 7.3.5.3. UK
    • 7.3.5.3.1. Market size and forecast, by Mode
    • 7.3.5.3.2. Market size and forecast, by Test Type
    • 7.3.5.3.3. Market size and forecast, by End-use
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Market size and forecast, by Mode
    • 7.3.5.4.2. Market size and forecast, by Test Type
    • 7.3.5.4.3. Market size and forecast, by End-use
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Market size and forecast, by Mode
    • 7.3.5.5.2. Market size and forecast, by Test Type
    • 7.3.5.5.3. Market size and forecast, by End-use
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Mode
    • 7.3.5.6.2. Market size and forecast, by Test Type
    • 7.3.5.6.3. Market size and forecast, by End-use
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Mode
  • 7.4.3. Market size and forecast, by Test Type
  • 7.4.4. Market size and forecast, by End-use
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Market size and forecast, by Mode
    • 7.4.5.1.2. Market size and forecast, by Test Type
    • 7.4.5.1.3. Market size and forecast, by End-use
    • 7.4.5.2. China
    • 7.4.5.2.1. Market size and forecast, by Mode
    • 7.4.5.2.2. Market size and forecast, by Test Type
    • 7.4.5.2.3. Market size and forecast, by End-use
    • 7.4.5.3. Australia
    • 7.4.5.3.1. Market size and forecast, by Mode
    • 7.4.5.3.2. Market size and forecast, by Test Type
    • 7.4.5.3.3. Market size and forecast, by End-use
    • 7.4.5.4. India
    • 7.4.5.4.1. Market size and forecast, by Mode
    • 7.4.5.4.2. Market size and forecast, by Test Type
    • 7.4.5.4.3. Market size and forecast, by End-use
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Market size and forecast, by Mode
    • 7.4.5.5.2. Market size and forecast, by Test Type
    • 7.4.5.5.3. Market size and forecast, by End-use
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Mode
    • 7.4.5.6.2. Market size and forecast, by Test Type
    • 7.4.5.6.3. Market size and forecast, by End-use
• 7.5. LAMEA
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Mode
  • 7.5.3. Market size and forecast, by Test Type
  • 7.5.4. Market size and forecast, by End-use
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Mode
    • 7.5.5.1.2. Market size and forecast, by Test Type
    • 7.5.5.1.3. Market size and forecast, by End-use
    • 7.5.5.2. Saudi Arabia
    • 7.5.5.2.1. Market size and forecast, by Mode
    • 7.5.5.2.2. Market size and forecast, by Test Type
    • 7.5.5.2.3. Market size and forecast, by End-use
    • 7.5.5.3. South Africa
    • 7.5.5.3.1. Market size and forecast, by Mode
    • 7.5.5.3.2. Market size and forecast, by Test Type
    • 7.5.5.3.3. Market size and forecast, by End-use
    • 7.5.5.4. Rest of LAMEA
    • 7.5.5.4.1. Market size and forecast, by Mode
    • 7.5.5.4.2. Market size and forecast, by Test Type
    • 7.5.5.4.3. Market size and forecast, by End-use

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. Abbott Laboratories
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
  • 9.1.7. Key strategic moves and developments
• 9.2. Gilead Sciences, Inc.
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
  • 9.2.7. Key strategic moves and developments
• 9.3. Merck & Co. Inc.
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
  • 9.3.7. Key strategic moves and developments
• 9.4. Danaher Corporation
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
  • 9.4.7. Key strategic moves and developments
• 9.5. Mylan N.V.
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
  • 9.5.7. Key strategic moves and developments
• 9.6. F Hoffman La Roche Ltd
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
  • 9.6.7. Key strategic moves and developments
• 9.7. Siemens Healthcare Private Limited
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
  • 9.7.7. Key strategic moves and developments
• 9.8. Qiagen NV.
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
  • 9.8.7. Key strategic moves and developments
• 9.9. Bio-Rad Laboratories, Inc.
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
  • 9.9.7. Key strategic moves and developments
• 9.10. Hologic Inc.
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance
  • 9.10.7. Key strategic moves and developments